These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

824 related items for PubMed ID: 18288745

  • 21. Incidence, timing, and predictive factors of new-onset migraine headache attack after transcatheter closure of atrial septal defect or patent foramen ovale.
    Rodés-Cabau J, Mineau S, Marrero A, Houde C, Mackey A, Côté JM, Chetaille P, Delisle G, Bertrand OF, Rivest D.
    Am J Cardiol; 2008 Mar 01; 101(5):688-92. PubMed ID: 18308022
    [Abstract] [Full Text] [Related]

  • 22. Predictors of recurrent events in patients with cryptogenic stroke and patent foramen ovale within the CLOSURE I (Evaluation of the STARFlex Septal Closure System in Patients With a Stroke and/or Transient Ischemic Attack Due to Presumed Paradoxical Embolism Through a Patent Foramen Ovale) trial.
    Elmariah S, Furlan AJ, Reisman M, Burke D, Vardi M, Wimmer NJ, Ling S, Chen X, Kent DM, Massaro J, Mauri L, CLOSURE I Investigators.
    JACC Cardiovasc Interv; 2014 Aug 01; 7(8):913-20. PubMed ID: 25147037
    [Abstract] [Full Text] [Related]

  • 23. Safety and long-term results of patent foramen ovale transcatheter closure in patients with thrombophilia.
    Rigatelli G, Dell'Avvocata F, Giordan M, Camerotto A, Panin S, Ronco F, Cardaioli P.
    Minerva Cardioangiol; 2009 Jun 01; 57(3):285-9. PubMed ID: 19513009
    [Abstract] [Full Text] [Related]

  • 24. [Chronic outcome of percutaneous transcatheter patent foramen ovale closure with Left-disk-coated patent foramen ovale occluder].
    Huang YG, Zhang CJ, Huang XS, Huang T, Huang WH.
    Zhonghua Xin Xue Guan Bing Za Zhi; 2009 Dec 01; 37(12):1132-5. PubMed ID: 20193187
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. Clinical and brain magnetic resonance imaging follow-up after percutaneous closure of patent foramen ovale in patients with cryptogenic stroke.
    Vigna C, Inchingolo V, Giannatempo G, Pacilli MA, Di Viesti P, Fusilli S, Amico CM, Santoro T, Lanna P, Fanelli R, Simone P, Loperfido F.
    Am J Cardiol; 2008 Apr 01; 101(7):1051-5. PubMed ID: 18359330
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. Outcomes after transcatheter closure of patent foramen ovale in patients with paradoxical embolism.
    Harms V, Reisman M, Fuller CJ, Spencer MP, Olsen JV, Krabill KA, Gray WA, Jesurum JT.
    Am J Cardiol; 2007 May 01; 99(9):1312-5. PubMed ID: 17478164
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. Percutaneous atrial shunt closure using the novel Occlutech Figulla device: 6-month efficacy and safety.
    Van Den Branden BJ, Post MC, Plokker HW, Ten Berg JM, Suttorp MJ.
    J Interv Cardiol; 2011 Jun 01; 24(3):264-70. PubMed ID: 21198853
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. Second transcatheter closure for residual shunt following percutaneous closure of patent foramen ovale.
    Susuri N, Obeid S, Ulmi M, Siontis GCM, Wahl A, Windecker S, Nietlispach F, Meier B, Praz F.
    EuroIntervention; 2017 Sep 20; 13(7):858-866. PubMed ID: 28437244
    [Abstract] [Full Text] [Related]

  • 35. Long term follow up after percutaneous closure of PFO in 357 patients with paradoxical embolism: Difference in occlusion systems and influence of atrial septum aneurysm.
    von Bardeleben RS, Richter C, Otto J, Himmrich L, Schnabel R, Kampmann C, Rupprecht HJ, Marx J, Hommel G, Münzel T, Horstick G.
    Int J Cardiol; 2009 May 01; 134(1):33-41. PubMed ID: 18715659
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. Transcatheter closure of patent foramen ovale (PFO) in patients with paradoxical embolism: procedural and follow-up results after implantation of the Amplatzer®-occluder device.
    Fischer D, Haentjes J, Klein G, Schieffer B, Drexler H, Meyer GP, Schaefer A.
    J Interv Cardiol; 2011 Feb 01; 24(1):85-91. PubMed ID: 20735710
    [Abstract] [Full Text] [Related]

  • 38. Electrocardiographic changes and arrhythmias following percutaneous atrial septal defect and patent foramen ovale device closure.
    Johnson JN, Marquardt ML, Ackerman MJ, Asirvatham SJ, Reeder GS, Cabalka AK, Cetta F, Hagler DJ.
    Catheter Cardiovasc Interv; 2011 Aug 01; 78(2):254-61. PubMed ID: 21563292
    [Abstract] [Full Text] [Related]

  • 39. Mid-term results of interventional closure of patent foramen ovale with the Occlutech Figulla® Flex II Occluder.
    Neuser J, Akin M, Bavendiek U, Kempf T, Bauersachs J, Widder JD.
    BMC Cardiovasc Disord; 2016 Nov 10; 16(1):217. PubMed ID: 27832757
    [Abstract] [Full Text] [Related]

  • 40. Late results after percutaneous closure of patent foramen ovale for secondary prevention of paradoxical embolism using the amplatzer PFO occluder without intraprocedural echocardiography: effect of device size.
    Wahl A, Tai T, Praz F, Schwerzmann M, Seiler C, Nedeltchev K, Windecker S, Mattle HP, Meier B.
    JACC Cardiovasc Interv; 2009 Feb 10; 2(2):116-23. PubMed ID: 19463412
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 42.